Clinical trials: Immunocompromised
Infections, Meningococcal
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy…
- Trial name
- NCT01641042
- Testing
- Meningococcal vaccine GSK134612
- Where
- 16 sites in United States, Czechia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Diseases, Fever
Pneumocystis Primary Infection in Non-immunosuppressed Infants
To determine the prevalence of P. jirovecii in nasopharyngeal aspirations of neonates and infants hospitalized for symptomatic respiratory infection.
- Trial name
- CAPRI-PC (NCT03740646)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Brest
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV or EBV in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
- Trial name
- NCT04364178
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jessie L. Alexander, MD
Invasive Aspergillosis, Pleural Effusion
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Diagnostic accuracy of biomarker testing (galactomannan (GM), (1
- Conditions
- Invasive Aspergillosis, Pleural Effusion, Immunosuppression
- Trial name
- EFFU-ASP (NCT02104479)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Heidelberg University
Cutaneous Squamous Cell Carcinoma of the Head and Neck
Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
In this prospective cohort study, investigators will conduct ultrasound surveillance of the nodal basins of patients with head and neck cutaneous squamous cell carcinoma (cSCC) whose tumors are considered high risk and staged by…
- Trial name
- NCT05956795
- Testing
- Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
SARS-CoV-2
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
- Trial name
- NCT05366322
- Where
- United States
- Volunteers
- 124,879 people
- Sponsor
- ModernaTX, Inc.
Aspergillosis, Aspergilloma
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down.
- Trial name
- NCT01383993
- Testing
- Voriconazole
- Where
- 6 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Pneumococcal Infection, ANCA-associated Vasculitis
Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Exploratory study of anti-pneumococcal immune response in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) immunized according to new vaccine recommendations (i.e.
- Trial name
- NCT02463578
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV-2 Infection
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell…
- Trial name
- TONI (NCT05141058)
- Testing
- Coronavirus-specific T cell (CST)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Children's National Research Institute
COVID-19, SARS-CoV-2
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.
- Conditions
- COVID-19, SARS-CoV-2, Immunocompromised
- Trial name
- SARS-CoV-2 (NCT06610643)
- Testing
- combination therapy, SOC
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Emerging Infectious Diseases and Their Treatments
Biological Collection on Emerging Infectious Diseases and Their Treatments
Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs).
- Trial name
- COMETE (NCT07674550)
- Where
- France
- Volunteers
- 5,300 people
- Sponsor
- University Hospital, Toulouse
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV-2 RNA Vaccines, HIV Infection
Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed
Prospective, non-equality, cohort study, where investigators propose to analyze humoral and cellular immunity after two doses of SARS-CoV-2 RNA vaccines in HIV-infected participants severely immunosuppressed.
- Trial name
- NCT05633927
- Testing
- SARS-CoV-2 Vaccine
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
HIV
Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza
As recommended by the Dutch Health Council, certain risk groups and health care workers in The Netherlands were vaccinated to prevent morbidity due to pandemic influenza A/H1N1.
- Trial name
- RICH-3 (NCT01066169)
- Testing
- Foceteria® (Novartis)
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Antibody-mediated Rejection
DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
Kidney transplantation is the best therapy method for patients with uremia. The main factors affecting the long-term survival of the graft were chronic antibody-mediated rejection and the death of the patients.
- Trial name
- DRFMBIPTP (NCT04368962)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Acute Lung Injury, Acute Respiratory Distress Syndrome
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Trial name
- GRAIL (NCT01335932)
- Testing
- IV Ganciclovir
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Immunocompromised Host, Critical Care
ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients
the number of immunocompromised patients hospitalized in the intensive care units (ICU) is increasing. They are at higher risk of colonization and/or infection with multi-resistant bacteria (MDR).
- Trial name
- CIMDREA (NCT04043793)
- Where
- 7 sites in France
- Volunteers
- 759 people
- Sponsor
- University Hospital, Lille
HSV
Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2
AiCuris Anti-infective Cures AG (AiCuris) is developing pritelivir for the oral treatment of acyclovir-resistant (ACV-R) mucocutaneous herpes simplex virus (HSV) infections in immunocompromised subjects.
- Trial name
- NCT05844436
- Testing
- Pritelivir
- Sponsor
- AiCuris Anti-infective Cures AG
Fungal Infection
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.
- Trial name
- NCT00292071
- Testing
- caspofungin acetate
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
H1N1 Pandemic Flu
Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults
This study will evaluate the immunogenicity and safety of inactivated H1N1 swine-origin monovalent influenza vaccine in immunocompromised children and young adults.
- Trial name
- NCT01000571
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- St. Jude Children's Research Hospital